Glofitamab
Last Updated: 04/28/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 148 publications
The pricing barrier: cost-effectiveness of Glofitamab for relapsed/refractory DLBCL in China beyond threshold and value-based pricing strategy considerations.
Journal: Expert review of anticancer therapy
Published: February 24, 2026
Refractory Burkitt Lymphoma Responding to an Accelerated Ramp-up of Glofitamab With Polatuzumab.
Journal: Clinical lymphoma, myeloma & leukemia
Published: February 02, 2026
Bispecific Antibodies in B-Cell Lymphomas: Mechanisms, Efficacy, Toxicity, and Management.
Journal: Medicina (Kaunas, Lithuania)
Published: January 06, 2026
Advances in the clinical application of bispecific antibodies in cancer therapy.
Journal: iScience
Published: January 01, 2026
Development and biomarkers of CD20/CD3 bispecific antibodies in diffuse large B-cell lymphoma.
Journal: Journal of clinical and experimental hematopathology : JCEH
Published: December 24, 2025
Bispecific antibody combination regimens for B-cell non-Hodgkin's lymphomas.
Journal: Expert opinion on biological therapy
Published: December 12, 2025
Current progress and latest therapeutic options in immuno-oncology
Journal: Deutsche medizinische Wochenschrift (1946)
Published: October 28, 2025
Patient preferences for attributes of bispecific antibodies for relapse/refractory diffuse large B-cell lymphoma in the US.
Journal: Future oncology (London, England)
Published: October 21, 2025
Efficacy and Safety of Glofitamab Plus Polatuzumab Vedotin in Relapsed/Refractory Large B-Cell Lymphoma Including High-Grade B-Cell Lymphoma: Results From a Phase Ib/II Trial.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: October 20, 2025
Last Updated: 04/28/2026